$533 Million is the total value of Meditor Group Ltd's 9 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 50.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
EXEL | Sell | EXELIXIS INC | $359,249,000 | +14.4% | 15,094,495 | -5.5% | 67.36% | +4.1% |
ESPR | ESPERION THERAPEUTICS INC | $107,595,000 | -12.7% | 2,679,835 | 0.0% | 20.17% | -20.5% | |
ALKS | ALKERMES PLC | $32,564,000 | +23.7% | 892,400 | 0.0% | 6.11% | +12.6% | |
INDA | ISHARES MSCI INDIA ETF | $11,280,000 | +6.0% | 320,000 | 0.0% | 2.12% | -3.6% | |
EPI | WISDOMTREE INDIA EARNINGS FUND | $10,532,000 | +6.2% | 400,000 | 0.0% | 1.98% | -3.3% | |
SDS | New | PROSHARES ULTRASHORT S&P 500 ETF | $3,828,000 | – | 115,000 | +100.0% | 0.72% | – |
SPXU | New | PROSHARES ULTRAPRO SHORT S&P 500 ETF | $3,312,000 | – | 105,000 | +100.0% | 0.62% | – |
SQQQ | New | PROSHARES ULTRAPRO SHORT QQQ ETF | $2,898,000 | – | 285,000 | +100.0% | 0.54% | – |
CLDX | Sell | CELLDEX THERAPEUTICS | $2,071,000 | +65.8% | 420,846 | -93.3% | 0.39% | +51.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-04-03
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
EXELIXIS INC | 43 | Q4 2023 | 88.9% |
ALKERMES PLC | 31 | Q4 2020 | 62.6% |
ISHARES MSCI INDIA ETF | 31 | Q4 2023 | 5.5% |
WISDOMTREE INDIA EARNINGS FUND | 31 | Q4 2023 | 5.5% |
ESPERION THERAPEUTICS INC | 27 | Q4 2023 | 34.4% |
VIVUS INC | 15 | Q4 2016 | 21.3% |
CELLDEX THERAPEUTICS | 14 | Q2 2020 | 2.7% |
PROSHARES ULTRAPRO SHORT S&P500 | 4 | Q4 2017 | 3.8% |
PROSHARES ULTRASHORT S&P500 | 4 | Q4 2017 | 3.0% |
PROSHARES ULTRASHORT S&P 500 ETF | 3 | Q3 2019 | 0.8% |
View Meditor Group Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
EXELIXIS, INC. | April 09, 2019 | 15,001,073 | 5.0% |
VIVUS INC | December 19, 2012 | 5,002,896 | 5.0% |
VIVUS INC | March 21, 2012 | 6,177,500 | 6.3% |
VION PHARMACEUTICALS INC | February 15, 2008 | 5,736,200 | 7.6% |
CYPRESS BIOSCIENCE INC | September 26, 2007 | 1,864,645 | 5.0% |
ONYX PHARMACEUTICALS INC | September 12, 2007 | 2,627,800 | 4.8% |
ACUSPHERE INC | July 26, 2007 | 1,839,421 | 4.0% |
NOVACEA INC | June 11, 2007 | 800,000 | 3.4% |
ATHEROGENICS INC | May 02, 2007 | 1,361,800 | 3.5% |
View Meditor Group Ltd's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-11 |
13F-HR | 2024-01-04 |
SC 13G/A | 2024-01-03 |
13F-HR | 2023-10-31 |
13F-HR | 2023-07-25 |
13F-HR | 2023-04-10 |
13F-HR | 2023-01-05 |
SC 13G/A | 2023-01-04 |
13F-HR | 2022-11-07 |
13F-HR | 2022-07-18 |
View Meditor Group Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.